Moderna posts first profit in two years, driven by Covid-19 vaccine sales, as it refocuses on cancer vaccines

Moderna reported a modest profit for the quarter, marking its first earnings surplus in two years. The turnaround was driven primarily by continued sales of its international Covid-19 vaccine portfolio.

The company said it is channeling resources toward developing cancer vaccines, signaling a strategic shift after the pandemic-era surge. Executives highlighted progress in early-stage programs and plans to expand the oncology pipeline.

Analysts view the profit as a positive sign of cash flow recovery, while the renewed emphasis on oncology could shape future growth and investor interest.